Altimmune Has Enrolled The First Subject In The Phase 2B IMPACT Trial Evaluating The Efficacy And Safety Of Pemvidutide In Subjects With Non-alcoholic Steatohepatitis; Topline Results Are Expected In Q1 2025
Portfolio Pulse from Benzinga Newsdesk
Altimmune has enrolled the first subject in the Phase 2B IMPACT trial evaluating the efficacy and safety of Pemvidutide in subjects with non-alcoholic steatohepatitis. Topline results are expected in Q1 2025.
August 01, 2023 | 11:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune has started the Phase 2B IMPACT trial for Pemvidutide. This could potentially impact the company's stock positively if the trial results are promising.
The initiation of a Phase 2B trial is a significant step in drug development. If the trial results are positive, it could lead to increased investor confidence and a potential rise in Altimmune's stock price. However, the results are not expected until Q1 2025, so the immediate impact may be limited.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100